KORU Medical Systems, Inc. (KRMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 7, 2025, announces the financial results for the first quarter ended March 31, 2025, and provides updated financial guidance for the fiscal year ending December 31, 2025. The Company operates in the medical systems sector and is listed on The Nasdaq Stock Market under the symbol KRMD.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
The Company highlights the use of the following non-GAAP financial measures to supplement GAAP results:
- Adjusted EBITDA: Defined as net income/loss before interest, depreciation, amortization, reorganization charges, litigation expenses, and stock-based compensation.
- Adjusted Diluted EPS: Adjusted for interest, depreciation, amortization, reorganization expenses, litigation expenses, and stock-based compensation to reflect ordinary operations.
Material Changes and Guidance
The Company has issued updated financial guidance for the full fiscal year 2025. Specific details regarding material changes versus the prior comparable period or the specific targets of the updated guidance are not disclosed in the 8-K text itself and must be reviewed in the attached press release (Exhibit 99.1).
Management Commentary and Risks
Management emphasizes that non-GAAP measures should not be considered replacements for GAAP measures and encourages investors to review the full consolidated financial statements. A reconciliation of GAAP to non-GAAP results is provided in the press release. The filing notes that the information in Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2025 revenue, net income, and cash flow figures.
- Verify the specific updated full-year 2025 revenue and earnings guidance targets.
- Examine the reconciliation table in the press release to understand the adjustments made to derive Adjusted EBITDA and Adjusted Diluted EPS.
- Confirm the date and time of the conference call (May 7, 2025, at 4:30 pm Eastern Time) for management commentary on the results.